In 2007 Williams et al. [24] noted that the well-established target of an entire class of type 2 diabetes drugs (PPARγ [25]) would not have been identified de novo by 3 GWA studies published that year [26-28] if traditional methods of GWAS validation were rigidly followed. This evidence concerns the gene PPARG and type 2 diabetes mellitus.